{
    "root": "b6245e25-3e64-40a8-a05e-d3b3e53cb787",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Quetiapine",
    "value": "20250306",
    "ingredients": [
        {
            "name": "QUETIAPINE FUMARATE",
            "code": "2S3PL1B6UJ"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "HYPROMELLOSE 2208 (100 MPA.S)",
            "code": "B1QE5P712K"
        },
        {
            "name": "HYPROMELLOSE 2208 (4000 MPA.S)",
            "code": "39J80LT57T"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "SODIUM CITRATE",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "Quetiapine is an atypical antipsychotic indicated for the treatment of: Schizophrenia. ( 1.1 ) Bipolar I disorder, manic, or mixed episodes. ( 1.2 ) Bipolar disorder, depressive episodes. ( 1.2 ) Major depressive disorder, adjunctive therapy with antidepressants. ( 1.3 )",
    "contraindications": "Swallow tablets whole and do not split, chew or crush. ( 2.1 ) Take without food or with a light meal (approx. 300 calories). ( 2.1 ) Administer once daily, preferably in the evening. ( 2.1 ) Geriatric Use: Consider a lower starting dose (50 mg/day), slower titration, and careful monitoring during the initial dosing period in the elderly. ( 2.3 , 8.5 ) Hepatic Impairment: Lower starting dose (50 mg/day) and slower titration may be needed. ( 2.4 , 8.7 , 12.3 ) Indication Initial Dose Recommended Dose Maximum Dose Schizophrenia - Adults ( 2.2 ) 300 mg/day 400 mg/day to 800 mg/day 800 mg/day Schizophrenia - Adolescents (13 to 17 years) ( 2.2 ) 50 mg/day 400 mg/day to 800 mg/day 800 mg/day Bipolar I Disorder manic or mixed - Acute monotherapy or adjunct to lithium or divalproex -Adults ( 2.2) 300 mg/day 400 mg/day to 800 mg/day 800 mg/day Bipolar I Disorder, manic Acute monotherapy -Children and Adolescents (10 to 17 years) ( 2.2 ) 50 mg/day 400 mg/day to 600 mg/day 600 mg/day Bipolar Disorder, Depressive Episodes - Adults ( 2.2 ) 50 mg/day 300 mg/day 300 mg/day Major Depressive Disorder, Adjunctive Therapy with Antidepressants - Adults ( 2.2 ) 50 mg/day 150 mg/day to 300 mg/day 300 mg/day",
    "warningsAndPrecautions": "Quetiapine Extended-Release Tablets USP, 400 mg are supplied as white to off-white, film-coated, modified capsule shaped tablets debossed with ‘AN431’ on one side and plain on other side.\n                  They are available as follows:\n                  Bottles of 60:                                       NDC 65162-431-06\n                  Store quetiapine extended-release tablets at 20° to 25ºC (68° to 77ºF); excursions permitted between 15° to 30ºC (59° to 86ºF) [see USP Controlled Room Temperature].",
    "adverseReactions": "Hypersensitivity to quetiapine or to any excipients in the quetiapine extended-release tablets formulation. Anaphylactic reactions have been reported in patients treated with quetiapine extended-release tablets."
}